China monoclonal antibody research forecast to increase

Several Chinese large-scale pharmaceutical enterprises have devoted themselves to research and development of monoclonal antibody agents, which have achieved results in 2013, according to a new report, titled Research on China Monoclonal Antibody (McAB) Industry, 2014, added to the offering of researchandmarkets.com.

Hengrui Medicine, Shanghai Pharmaceuticals and Qilu Pharm have all applied for clinical research of monoclonal antibody agents. Walvax Biotechnology also made a huge investment in purchasing Genor Biopharma, attempting to establish a large biological strategy. Although large-scale pharmaceutical enterprises entered monoclonal antibody field on a large scale, the overall innovation is still insufficient, and the market is represented by monoclonal antibody agents and biological analogue that have submitted applications, few imitated drugs, and innovative medicines are rare and precious things, mainly on account of high risks and long-time cycle.

$618 million market in 2013